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carla.giordano@unipa.itAbstractObjective: On the basis of the known diabetes risk in polycystic ovary syndrome (PCOS), recent guidelines of the Endocrine
Society recommend the use of an oral glucose tolerance test (OGTT) to screen for impaired glucose tolerance (IGT) and type 2
diabetes (T2DM) in all women with PCOS. However, given the high prevalence of PCOS, OGTT would have a high cost–benefit
ratio. In this study, we identified, through a receiver operating characteristic analysis, simple predictive markers of the
composite endpoint (impaired fasting glucose (IFG) or IGT or IFGCIGT or T2DM) in women with PCOS according
to the Rotterdam criteria.
Design: We conducted a cross-sectional study of 241 women with PCOS in a university hospital setting.
Methods: Clinical, anthropometric, and metabolic (including OGTT) parameters were evaluated. The homeostasis model
assessment of insulin resistance (HOMA2-IR), the Matsuda index of insulin sensitivity, and the oral dispositional index
and visceral adiposity index (VAI) were determined.
Results: Out of 241 women included in this study, 28 (11.6%) had an IFG, 13 (5.4%) had IGT, four (1.7%) had IFGCIGT, and
four (1.7%) had T2DM. Among the anthropometric variables examined, the VAI had a significantly higher C-statistic
compared with BMI (0.760 (95% CI: 0.70–0.81) vs 0.613 (95% CI: 0.54–0.67); PZ0.014) and waist circumference (0.760 (95% CI:
0.70–0.81) vs 0.619 (95% CI: 0.55–0.68); PZ0.028). Among all the hormonal and metabolic serum variables examined, DHEAS
showed the highest C-statistic (0.720 (95% CI: 0.65–0.77); P!0.001).
Conclusions: In addition to fasting glucose, the VAI and DHEAS may be considered useful tools for prescreening in all women
with PCOS without the classical risk factors for diabetes.European Journal of
Endocrinology
(2015) 172, 79–88IntroductionPolycystic ovary syndrome (PCOS) is the most common
endocrine disorder among women of reproductive age,
with a prevalence of between 5 and 20% (according to the
diagnostic criteria used) (1, 2, 3). In addition to chronic
anovulation and hyperandrogenism (clinical and bio-
chemical), PCOS is also associated with insulin resistance
(4, 5) and an increased risk of glucose intolerance and
type 2 diabetes mellitus (T2DM) (6, 7, 8), dyslipidemia,
subclinical atherosclerosis, and vascular dysfunction,
independently of BMI (5). It is known that women withPCOS have a five- to tenfold increased risk of developing
T2DM (6, 7, 8).
Owing to this high risk of impaired glucose tolerance
(IGT) and T2DM in women with PCOS (even without imp-
aired fasting glucose (IFG)), periodic screening of patients
to detect early abnormalities in glucose tolerance is recom-
mended by several scientific organizations, although a time
interval for screening has not been specified (9, 10, 11).
The Endocrine Society has recently issued clinical
practice guidelines on the diagnosis and treatment of
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172 :1 80PCOS (12), in which they recommend the use of an
oral glucose tolerance test (OGTT) (fasting and a 2-h
glucose level using a 75 g oral glucose load) to screen
for IGT and T2DM in all adolescents and adult women
with PCOS because they are at high risk for such
abnormalities. Rescreening is suggested every 3–5 years,
or more frequently if clinical factors such as central
adiposity, substantial weight gain, and/or symptoms of
diabetes develop.
This procedure, however, has its costs, given the
high prevalence of PCOS, and especially its chronicity.
In addition, we must also consider that the large
phenotypic variability of PCOS (13), also influenced by
environmental factors, may change during fertile life
(changes in the degree of hyperandrogenism, menstrual
dysfunction, weight, and insulin resistance). This
implies that some women, even if they do not meet
the full diagnostic criteria of PCOS at a given time, can
nonetheless have a high risk of diabetes. In case of
normal fasting glucose levels, it would be useful to have
simple prescreening tools for diabetes, to be used both
in overt PCOS and in the presence of a single diagnostic
criterion of Rotterdam.
In the current study, through a receiver operating
characteristic (ROC) analysis, we wanted to evaluate
whether simple anthropometric and/or laboratory para-
meters may be predictive of the composite endpoint
(IFG or IGT or IFGCIGT or T2DM) in women with PCOS
(according to the Rotterdam criteria).Subjects and methods
Subjects
This study was approved by the Institutional Review
Board at the Faculty of Medicine of the University of
Palermo. At the time of observation in our Gynecologic
Outpatients Endocrinology Unit, all patients regularly
signed an informed consent for the scientific use of
their data. It involved a cross-sectional study of 340
consecutive Caucasian women, aged 14–44 years followed
up in our outpatients clinic (from January 1st 2005 to
December 31st 2013) for hirsutism and/or other signs
and symptoms of hyperandrogenism (acne/seborrhea
and alopecia) and/or irregular menstrual cycles (oligo-
amenorrhea). Applying the Rotterdam diagnostic criteria
(14), we retrospectively selected 241 of these women
(70.8%) with PCOS.
The following subjects were excluded from the
study: a small number of women (32/340 cases) withwww.eje-online.orgamenorrhea at the moment of observation (absence of
vaginal bleeding O6 months), and those with various
progesterone bleeding induction schemes, potentially
interfering with sex hormone patterns; women treated
with clomiphene citrate, oral contraceptives, antiandro-
gens, drugs to control their appetite or insulin-sensitizing
drugs (metformin, pioglitazone, and rosiglitazone) during
the 6 months before the first examination; women with
hyperprolactinemia (5/340 cases); patients with 17-OH
progesterone levels O6.05 nmol/l who, after 250 mg
Synacthen (synthetic analog of ACTH), showed 17-OH
progesterone O30.26 nmol/l at 60 min (3/340 cases);
women with DHEASO16.32 mmol/l, who, when screened
with a computerized axial tomography scan, presented
adrenal hyperplasia or adenoma or virilizing androgen-
secreting neoplasias (1/340 cases); and women whose
clinical and hormone evaluation (phenotype, increased
24-h free urinary cortisol, and high cortisol levels after
1 mg of overnight dexamethasone) suggested Cushing’s
syndrome (4/340 cases). Women with hypo- or hyper-
thyroidism were also not taken into consideration for the
study. Out of 340 women, 54 were excluded because,
according to the Rotterdam criteria, they had only one
diagnostic criterion for PCOS.
The following relevant data were obtained from our
database: a possible family history of diabetes, oligo-
amenorrhea, hirsutism, acne, and age of menarche;
weight, BMI, waist circumference (WC), blood pressure,
and Ferriman–Gallwey (FG) score. It is a routine practice
in our Gynecologic Outpatients Endocrinology Unit to
evaluate the degree of hirsutism using the FG map
scoring system, which divides the body up into 11
domains. Hirsutism was defined as an FG score O8 (15).
The patients were tested for FSH, LH, 17b-estradiol (E2),
17-OH progesterone, basal prolactin, total testosterone,
DHEAS, D4-androstenedione, and sex hormone-binding
globulin (SHBG), during the follicular phase (day 7 from
the beginning of the last period). On the same day, we
also tested for total cholesterol, HDL cholesterol, LDL
cholesterol, triglycerides, glutamic–pyruvic transaminase
(GPT), glutamic-oxaloacetic transaminase (GOT), and
uric acid, performed an OGTT (75 g glucose), and
measured glycemia and insulinemia at 0, 30, 60, 90,
and 120 min. Serum progesterone level was determined
between days 20 and 24 of the menstrual cycle and
chronic oligoanovulation was established if two
consecutive cycles were anovulatory (progesterone level
!3 ng/ml (international system (SI): !9.54 nmol/l))
(16). Biochemical hyperandrogenism was diagnosed
when the androgen levels were as follows: total
E
u
ro
p
e
a
n
Jo
u
rn
a
l
o
f
E
n
d
o
cr
in
o
lo
g
y
Clinical Study M C Amato and others Polycystic ovary syndrome and
diabetes risk
172 :1 81testosterone O2.84 nmol/l, DHEASO12.14 mmol/l, and
D4-androstenedione O10.72 nmol/l (calculated on the
basis of the 95th percentile upper limits of basal serum
androgen normality in 144 healthy Sicilian eumenor-
rheal women without hirsutism and a family history of
PCOS (used as a control group in our previous study
(17))). Transvaginal ovarian ultrasound scanning was
performed between days 5 and 10 from the beginning of
the last period using a 7.5-MHz vaginal probe transducer
(General Electric LOGIQ 400MD, Milwaukee, WI, USA).
Both ovaries were measured in the sagittal, transverse,
and coronal planes. Ovaries were classified as polycystic
if 12 or more follicles measuring 2–8 mm in diameter
were present in each ovary, and/or there was an increase
in the ovarian volume (O10 ml) (18).
Metabolic syndrome (MetS) was diagnosed according
to the National Cholesterol Education Program Adult
Treatment Panel (NCEP-ATP) III definition (19) and
diagnosis of diabetes mellitus according to the recom-
mendations of the American Diabetes Association (20).
Patients with prediabetes were defined as having IFG
(fasting plasma glucose (FPG) levels 5.6–6.9 mmol/l),
or IGT (2-h after OGTT plasma glucose levels of
7.8–11.0 mmol/l), or IFGCIGT.Assays
All hormones were measured in our laboratory using
commercial kits. These included ELISA (DRG Diagnos-
tics, DRG Instruments GmbH, Marburg, Germany) for
FSH (mUI/ml; analytical sensitivity: 0.85 mUI/ml; the
intra- and interassay CV values were 4.50 and 5.84%
respectively), LH (mUI/ml; analytical sensitivity:
1.27 mUI/ml; the intra- and interassay CV values were
4.54 and 3.22% respectively), 17b-E2 (pg/ml; analytical
sensitivity: 9.71 pg/ml; the intra- and interassay CV
values were 2.71 and 6.72% respectively), 17-OH
progesterone (ng/ml; analytical sensitivity: 0.034 ng/ml;
the intra- and interassay CV values were 5.40 and
6.17% respectively), Pg (ng/ml; analytical sensitivity:
0.045 ng/ml; the intra- and interassay CV values were
5.40 and 4.34 respectively), PRL (ng/ml; analytical
sensitivity: 0.35 ng/ml; the intra- and interassay CV
values were 2.91 and 5.64% respectively), total testo-
sterone (ng/ml; analytical sensitivity: 0.083 ng/ml; the
intra- and interassay CV values were 3.28 and 4.73%
respectively), D4-androstenedione (ng/ml; Arnika, Milan,
Italy; analytical sensitivity: 0.021 ng/ml; the intra- and
interassay CV values were 5.30 and 8.10% respectively)),
and insulin (mUI/l; the intra- and interassay CV valueswere %4 and %3.6% respectively). Chemiluminescence
assays were used for DHEAS (mg/dl; Immulite, Diagnostic
Products, Genoa, Italy; analytical sensitivity: 15 mg/dl;
the intra- and interassay CV values were 6.30 and 6.90%
respectively) and serum SHBG (nmol/l; Immulite, Diag-
nostic Products, Genoa, Italy; analytical sensitivity:
0.015 nmol/l; the intra- and interassay CV values were
5.50 and 6.20% respectively). Blood glucose levels
(mg/dl) were measured using an electrochemical system
(Glucocard, Menarini Diagnostics, Florence, Italy). Total
cholesterol, HDL, triglycerides, GOT, GPT, and uric acid
were measured in our laboratory using standard assays.
LDL cholesterol levels were calculated with Friedewald’s
formula. The conversion factors for the SI were the
following: glucose (mg/dl vs mmol/l: 0.0555), insulin
(mUI/l vs pmol/l: 6.945), total cholesterol (mg/dl vs
mmol/l: 0.0259), total testosterone (ng/ml vs nmol/l:
3.467), free testosterone (pg/ml vs pmol/l: 3.47), DHEAS
(mg/dl vs mmol/l: 0.0272), D4-androstenedione (ng/ml vs
nmol/l: 3.492), E2 (pg/ml vs pmol/l: 3.671), 17-OH
progesterone (ng/ml vs nmol/l: 3.026), Pg (ng/ml vs
nmol/l: 3.180), PRL (ng/ml vs mg/l: 1), FSH (mUI/ml vs
IU/l: 1), and LH (mUI/ml vs IU/l: 1).
Free androgen index was calculated as the ratio of
total testosterone levels in nmol/l to SHBG levels in
nmol/lt!100 (%) (21). Insulin sensitivity was estimated
indirectly using fasting plasma insulin and FPG to
calculate the homeostasis model of insulin resistance
(HOMA2-IR) (calculations were performed using a free
software provided by the University of Oxford Diabetes
Trial Unit (http://www.dtu.ox.ac.uk/homacalculator))
and using glucose and insulin values during the OGTT
to calculate the Matsuda index of insulin sensitivity
(ISI Matsuda) (22) (10 000/glucose (mg/dl)!insulin
(mU/ml)!glucose mean!insulin mean). A composite
measure of b-cell function relative to insulin sensitivity,
assessed by oral disposition index (DIO) (23), was
calculated as (DInsulin0–30/DGlucose0–30)! (1/fasting
insulin). The trapezoidal method was used for the
calculation of the areas under the curves for insulin
(AUC2 h insulin) and glucose (AUC2 h glucose).
The visceral adiposity index (VAI) was calculated
as described (24) using the following sex-specific
equations:
where TG is triglyceride levels expressed in
mmol/l and HDL is HDL cholesterol levels expressed
in mmol/l.
Females : VAIZ
WC
36:58C ð1:89!BMIÞ
 
!
TG
0:81
 
!
1:52
HDL
 
:www.eje-online.org
Table 1 Clinical, anthropometric and biochemical charac-
teristics of the 241 women with PCOSa. Data are presented as
meanGS.D. (range) or as n (%).
Characteristics Values
Age (years) 24.39G6.17 (14–43)
BMI (kg/m2) 30.01G6.87 (18–50)
Age of menarche (years) 11.93G1.40 (9–17)
Waist circumference (cm) 91.75G17.44 (54–138)
Waist-to-hip ratio (WHR) 0.82G0.09 (0.59–1.17)
FG score 13.31G6.92 (1–35)
Classes of obesityb
Underweight 4 (1.7%)
Normal weight 67 (27.8%)
Overweight 67 (27.8%)
Obese class I 43 (17.8%)
Obese class II 40 (16.6%)
Obese class III 20 (8.3%)
Cigarette smoking 42 (17.4%)
Dyslipidemia
Increased non-HDL-C:O4.14 mmol/lc 83 (34.4%)
Increased LDL-C: O3.37 mmol/lc 57 (23.7%)
Metabolic syndromed 39 (16.2%)
Diabetes or fasting glucoseR5.6
mmol/l
31 (12.9%)
High blood pressure (R130/85 mmHg) 14 (5.8%)
High triglycerides (R1.7 mmol/l) 36 (14.9%)
Low HDL cholesterol (!1.04 mmol/l) 96 (39.8%)
Increased WC (O88 cm) 131 (54.4%)
Impaired fasting glucose (IFG) 28 (11.6%)
Impaired glucose tolerance (IGT) 13 (5.4%)
IFGCIGT 4 (1.7)
Diabetes mellitus 4 (1.7%)
Hormonal profiles
FSH (IU/l) 6.60G2.78 (1.00–21.70)
LH (IU/l) 8.38G4.53 (0.30–24.00)
17b-E2 (pmol/l) 191.81G99.29 (30.95–587.36)
17OHPg (nmol/l) 4.35G2.91 (0.51–20.58)
Pg (nmol/l) 12.55G17.43 (0.29–89.68)
Total testosterone (nmol/l) 2.22G1.43 (0.07–11.09)
SHBG (nmol/l) 68.42G42.48 (10.00–200.00)
FAI (100!(Total Testosterone/ 5.31G5.98 (0.18–42.49)
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The Statistical Packages for Social Sciences SPSS version
17 were used for the explorative data analysis. Baseline
characteristics were expressed as meanGS.D. and range
for continuous variables; rates and proportions were
calculated for categorical data. The normality of distri-
bution for quantitative variables was assessed using
the Shapiro–Wilk test. Differences between Groups A
and B in univariate analysis were detected by unpaired
Student’s t test for continuous variables (after testing
for equality of variance: Levene’s test) and by the c2-test
and Fisher’s exact test (when appropriate) for categorical
variables. For comparison between Groups A and B,
the group sizes provided 90% power to detect a moderate
effect size (Cohen’s dZ0.5) using the T-test, with a error
at 0.05. Post-hoc power analysis was performed using
the G*Power Version 3.1.6 Software. The ROC curve
analysis was conducted using the MedCalc software v.
9.3.8.0 for Windows (which uses calculation of the
area under the curve (C-statistic) and 95% CIs by
the technique of Hanley and McNeil), to evaluate the
diagnostic performance of the various parameters
(BMI, WC, total testosterone, DHEAS, total cholesterol,
non-HDL cholesterol, triglycerides, uric acid, and VAI)
for predicting an altered glucose tolerance (IFG or IGT
or IFGCIGT or T2DM). The differences between
C-statistics were calculated by the method of Hanley
and McNeil.
Some linear regression models were performed in
order to correct the correlations between DHEAS and
the various indices of insulin resistance for age and BMI.
A P value of!0.05 was considered statistically significant.
SHBG)) (%)
DHEA-S (mmol/l) 8.00G4.99 (1.33–23.61)
D4androstenedione (nmol/l) 9.79G6.91 (1.05–45.40)
Metabolic profiles
Homa2-IR 2.28G1.33 (0.40–7.20)
ISI Matsuda 3.83G3.00 (0.25–23.00)
AUC2 h insulin (pmol/l per 120 min) 11 090G6870 (762–36 540)
AUC2 h glucose (mmol/l per 120 min) 765G148 (477–1401)
Oral dispositional index (DIo) 4.27G11.47 (0.05–96.10)
VAI 1.82G1.06 (0.19–5.96)
Total cholesterol (mmol/l) 5.21G1.19 (2.94–11.56)
HDL cholesterol (mmol/l) 1.32G2.28 (0.17–2.19)
Calculated LDL cholesterol (mmol/l) 3.00G1.07 (0.95–8.85)
Non-HDL cholesterol (mmol/l) 3.88G1.21 (1.60–10.58)
Triglycerides (mmol/l) 1.18G0.55 (0.29–4.35)
Uric acid (mmol/l) 4.23G1.69 (1.8–9.6)
Glutamic oxaloacetic transaminase
(GOT) (U/l)
21.13G7.74 (11.00–68.00)
Glutamic pyruvate
transaminase (GPT) (U/l)
24.72G14.91 (7.00–129.00)
aAccording to Rotterdam Consensus 2003 (ESHRE/ASRM).
bWHO classification (2010).
cAccording to Consensus Statement (AE-PCOS) Society (Wild et al. (34)).
dAccording to Adult Treatment Panel (ATP) III criteria.Results
The demographic, clinical, and biochemical characteris-
tics (including anthropometric measurements, hormonal
profile, and metabolic profile) of the 241 women with
PCOS are presented in Table 1. The prevalence of
alterations in glucose tolerance was as follows: IFG
28/241 (11.6%), IGT 13/241 (5.4%), IGTCIGT 4/241
(1.7%), and T2DM 4/241 (1.7%). The composite endpoint
(IFG or IGT or IFGCIGT or T2DM) was present in
49 women with PCOS (20.3%) (Group B) (Table 2).
The remaining 192 women who had normal glucose
tolerance (Group A) showed a significantly lower BMI and
a WC compared with Group B (29.54G6.97 vs 31.87G
6.22 kg/m2, PZ0.025; 90.41G17.48 vs 97.01G16.40 cm,
PZ0.015 respectively). Group B showed a higherwww.eje-online.org
Table 2 Clinical, anthropometric, and biochemical differences between women with PCOS and normal glucose
tolerance (Group A) and women with PCOS and altered glucose tolerance (IFG or IGTor IFGCIGTor T2DM) (Group B).
Data are presented as meanGS.D. or as n(%).
Group A (nZ192) Group B (nZ49) P
Age (years) 24.08G6.17 25.61G6.05 0.119
BMI (kg/m2) 29.54G6.97 31.87G6.22 0.025
Age of menarche (years) 11.98G1.45 11.77G1.19 0.315
Waist circumference (cm) 90.41G17.48 97.01G16.40 0.015
Waist-to-hip ratio (WHR) 0.82G0.09 0.83G0.10 0.511
FG score 13.22G7.05 13.67G6.46 0.667
Phenotypic aspects
Hirsutism 142 (74.0%) 41 (83.7%) 0.156
Hormonal hyperandrogenism 94 (49.0%) 28 (57.1%) 0.306
Polycystic ovary morphology (PCOM) 146 (76.0%) 35 (71.4%) 0.505
Oligo-amenorrhea 140 (72.9%) 40 (81.6%) 0.210
Cigarette smoking 36 (18.8%) 6 (12.2%) 0.284
Dyslipidemia (increased non-HDL cholesterol) 58 (30.2%) 25 (51.0%) 0.006
Dyslipidemia (increased LDL cholesterol) 39 (20.3%) 18 (36.7%) 0.016
Metabolic syndromea 20 (10.4%) 19 (38.8%) !0.001
Diabetes or fasting glucose R5.6 mmol/l – 31 (63.3%) !0.001
High blood pressure (R130/85 mmHg) 9 (4.7%) 5 (10.2%) 0.141
High triglycerides (R1.7 mmol/l) 24 (12.5%) 12 (24.5%) 0.036
Low HDL cholesterol (!1.04 mmol/l) 68 (35.4%) 28 (57.1%) 0.006
Increased WC (O88 cm) 96 (50%) 35 (71.4%) 0.007
Hormonal profiles
FSH (IU/l) 6.50G2.43 6.98G3.86 0.300
H (IU/l) 8.27G4.41 8.78G5.00 0.532
17b-E2 (pmol/l) 194.29G102.45 181.74G85.57 0.395
17-OH progesterone (nmol/l) 4.15G2.83 5.15G3.12 0.056
Pg (nmol/l) 13.56G18.22 8.56G13.35 0.080
total testosterone (nmol/l) 2.12G1.26 2.63G1.94 0.027
SHBG (nmol/l) 70.12G42.51 61.77G42.12 0.221
FAI (100!(total testosterone/SHBG)) (%) 4.99G5.73 6.55G6.80 0.145
DHEAS (mmol/l) 7.31G4.07 10.70G5.06 !0.001
D4-androstenedione (nmol/l) 9.20G5.68 12.10G10.16 0.060
Metabolic profiles
HOMA2-IR 2.18G1.26 2.67G1.54 0.046
ISI Matsuda 4.06G3.10 2.94G2.41 0.008
AUC2 h insulin (pmol/l!120 min) 10 790G6841 12 266G6 930 0.186
AUC2 h glucose (mmol/l!120 min) 728G104 907G203 !0.001
Oral dispositional index (DIO) 3.11G5.19 8.85G22.88 0.002
VAI 1.63G0.93 2.53G1.23 !0.001
Total cholesterol (mmol/l) 5.12G1.03 5.57G1.66 0.017
HDL cholesterol (mmol/l) 1.34G0.28 1.27G0.99 0.053
Calculated LDL cholesterol (mmol/l) 2.94G1.07 3.21G1.04 0.212
Non-HDL cholesterol (mmol/l) 3.78G1.04 4.30G1.68 0.007
Triglycerides (mmol/l) 1.14G0.49 1.33G0.73 0.031
Uric acid (mmol/l) 4.00G1.53 4.92G1.96 0.004
GOT (U/l) 20.68G6.75 22.65G10.38 0.153
GPT (U/l) 23.71G12.83 27.95G20.08 0.193
IFG, impaired fasting glucose; IGT, impaired glucose tolerance; T2DM, type 2 diabetes mellitus.
aAccording to ATP III criteria.
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individual components (except for high blood pressure;
Table 2).
With regard to the hormonal profile, the
only differences found between the two groups were
significantly higher levels of total testosterone(2.63G1.94 nmol/l vs 2.12G1.26 nmol/l, PZ0.027)
and DHEAS (10.70G5.06 mmol/l vs 7.31G4.07 mmol/l,
P!0.001) in Group B.
The metabolic profile of Group B was significantly
altered compared with Group A, especially with regard
to HOMA2-IR, ISI Matsuda, AUC2 h glucose, DIO, VAI, totalwww.eje-online.org
Table 3 Optimal cutoff points of the various parameters able to predict an altered glucose tolerance
(IFG or IGT or IFGCIGT or T2DM).
Cutoff
point Sens. (%) Spec. (%)
Area under
ROC curve S.E.M. 95% CI P
BMI 28.4 71.43 53.13 0.613 0.046 0.54–0.67 0.015
WC 91 77.55 55.21 0.619 0.046 0.55–0.68 0.011
Total testosterone 1.38 87.76 32.29 0.556 0.047 0.49–0.62 0.233
DHEAS 8.43 71.43 69.79 0.720 0.044 0.65–0.77 !0.001
Total cholesterol 5.98 32.65 88.54 0.558 0.047 0.49–0.62 0.219
Non-HDL cholesterol 4.97 32.65 91.67 0.578 0.047 0.51–0.64 0.097
Triglycerides 1.54 38.78 82.29 0.569 0.047 0.50–0.63 0.142
Uric acid 4.9 53.85 70.18 0.626 0.053 0.54–0.70 0.019
VAI 1.82 71.43 75.00 0.760 0.042 0.70–0.81 !0.001
WC, waist circumference; VAI, visceral adiposity index. Sens., sensitivity; Spec., specificity.
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172 :1 84cholesterol, non-HDL cholesterol, triglycerides, and uric
acid (Table 2).Table 4 Differences between C-statistics of the predictor
variables of altered glucose tolerance (IFG or IGT or IFGCIGT
or T2DM).
Difference
between
C-statistics S.E.M. 95% CI P
BMI vs WC 0.040 0.03 K0.03 to 0.11 0.268
BMI vs DHEAS 0.087 0.07 K0.05 to 0.23 0.236ROC curve analysis
Any variables that showed significant differences between
the two groups (excluding those arising from the
execution of an OGTT) were subjected to a ROC curve
analysis in order to identify the optimal cutoff points
associated with the composite endpoint (IFG or IGT or
IFGCIGT or T2DM).
C-statistics were 0.613 (95% CI 0.54–0.67; PZ0.015)
for BMI, 0.619 (95%CI 0.55–0.68; PZ0.011) forWC, 0.556
(95% CI 0.49–0.62; PZ0.233) for total testosterone, 0.720
(95% CI 0.65–0.77; P!0.001) for DHEAS, 0.558 (95% CI
0.49–0.62; PZ0.219) for total cholesterol, 0.578 (95% CI
0.51–0.64; PZ0.097) for non-HDL cholesterol, 0.569 (95%
CI 0.50–0.63; PZ0.142) for triglycerides, 0.626 (95% CI
0.54–0.70; PZ0.019) for uric acid, and 0.760 (95%CI 0.70–
0.81; P!0.001) for VAI (Table 3). Among the variables
that showed a significant C-statistic, the VAI and DHEAS
showed a significantly greater area under the ROC curve
(Table 4 and Fig. 1). The threshold levels, calculated by
maximizing the combined specificity and sensitivity in
the ROC curves, were 1.82 (sensitivity: 71.43% and
specificity: 75.0%) for VAI and 8.43 mmol/l (sensitivity:
71.43% and specificity: 69.79%) for DHEAS.BMI vs uric acid 0.016 0.06 K0.10 to 0.13 0.781
BMI vs VAI 0.161 0.06 0.03 to 0.29 0.014
WC vs DHEAS 0.046 0.07 K0.09 to 0.19 0.528
WC vs uric acid 0.024 0.05 K0.08 to 0.13 0.671
WC vs VAI 0.121 0.05 0.01 to 0.22 0.028
DHEAS vs uric acid 0.070 0.07 K0.07 to 0.21 0.329
DHEAS vs VAI 0.074 0.06 K0.05 to 0.20 0.275
Uric acid vs VAI 0.145 0.06 0.02 to 0.26 0.020
WC, waist circumference; VAI, visceral adiposity index.Correlations between insulin sensitivity indices
and DHEAS
Given the association between DHEAS and diabetes
shown, and considering the changes in DHEAS related
to age and body weight (25, 26, 27, 28), some linear
regression models were performed to evaluate the effectwww.eje-online.orgof DHEAS (adjusted for age and BMI) on the various
parameters of insulin sensitivity and secretion examined.
DHEAS correlated independently with AUC2 h glucose
(bZ0.156, PZ0.013) and DIO (bZ0.166, PZ0.011);
no correlation was found with HOMA2-IR (bZK0.093,
PZ0.135), ISI Matsuda (bZ0.015, PZ0.818), and
AUC2 h insulin (bZK0.047, PZ0.464).Discussion
Although it is known that a diagnosis of PCOS in
adolescent and adult women confers up to a tenfold
increased risk of developing T2DM (6, 7, 8), our Sicilian
Caucasian women with PCOS had a relatively low
prevalence of T2DM (1.7%). These data are comparable
to reports in the literature of non-obese womenwith PCOS
(1–2%) (6, 7, 8), but 170 women (70.5%) in our series had
a higher BMI than 30 kg/m2. Instead, what characterized
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Figure 1
Comparison of ROC curves predictive of the composite endpoint
(impaired fasting glucose (IFG), impaired glucose tolerance
(IGT), IFGCIGT, and type 2 diabetes mellitus (T2DM)).
E
u
ro
p
e
a
n
Jo
u
rn
a
l
o
f
E
n
d
o
cr
in
o
lo
g
y
Clinical Study M C Amato and others Polycystic ovary syndrome and
diabetes risk
172 :1 85our women with PCOS was the high prevalence of
prediabetes, especially IFG (11.6%): these patients, as
recommended by the diabetologic guidelines (20), should
certainly be screened by an OGTT, regardless of whether
they are affected by PCOS.
Given the high prevalence of PCOS in women of
childbearing age, and given the known association with
diabetes, several studies have attempted to identify simple
screening tools that are alternatives to OGTT, usable in
the case of normal fasting glucose. One of these is glyco-
hemoglobin, which, however, has shown poor sensitivity
for detecting IGT in women with PCOS (29, 30); therefore,
it should only be considered a valid measure in the case
of overt T2DM.
In our study, we identified two simple parameters that
showed good sensitivity and specificity for detecting an
altered glucose tolerance: the VAI (cutoff point: 1.82) and
the DHEAS measuredinthe follicular phase (cutoff point:
8.43 mmol/l).
With regard to the application of the VAI in women
with PCOS, there are several studies that confirm it to be
an indicator of cardiometabolic risk (31). In our first
study (17), it was found that the oligo-menorrhoic
phenotypes of PCOS (applying the Rotterdam criteria)
were characterized by a high VAI and a condition ofcardiometabolic risk. In young Korean women with PCOS,
the VAI positively correlated with the visceral fat area
(measured with computed tomography) and the visceral-
to-subcutaneous fat ratio, but negatively correlated
with the insulin-mediated glucose utilization (M value)
during euglycemic hyperinsulinemic clamp (32). Another
recent study has demonstrated that the VAI increases in
relation to the severity of anovulation, insulin resistance,
and inflammation in women with PCOS (33). Recently,
these findings have led us to verify whether it was possible
to distinguish women with metabolically healthy PCOS
(MH-PCOS) from women with metabolically unhealthy
PCOS (MU-PCOS) using simple diagnostic tools such as
BMI, waist-to-hip ratio, the at-risk category suggested
by the Androgen Excess Society (34), and the VAI: among
all the criteria studied a VAI O1.675 showed the best
predictive value in detecting an adverse metabolic profile
in women with PCOS (35).
Thus, by putting together the results from these
previous studies with those of the present study, we can
state that a VAIO1.67 is already indicative of a MU-PCOS
and a VAI O1.82 is indicative of a MU-PCOS with a high
risk of diabetes. Obviously, prospective studies over a
period of at least 10 years are needed in order precisely
to quantify this risk in the future.
With regard to the use of the DHEAS as a marker of
diabetes risk in women with PCOS, the issue is more
controversial than the VAI, suggesting that there are even
studies showing a negative correlation between DHEAS
and insulin resistance in women with PCOS (36) and in
obese women with T2DM (37). In our study, not only did
we find significantly higher DHEAS levels in the group
with altered glucose tolerance, but also this parameter
at ROC analysis showed a significant area under the ROC
curve, which indicated good sensitivity and specificity
for the identification of this group of patients.
It is known that elevated serum levels of DHEAS
and 11b-hydroxyandrostenedione are found in 20–50%
of women with PCOS (38, 39, 40, 41) and these women
show generalized hypersecretion of adrenocortical pro-
ducts (pregnenolone, 17-hydroxypregnenolone, DHEA,
D4-androstenedione, and possibly cortisol) basally and in
response to ACTH administration (42). Moreover, the
increased levels of DHEAS may be the sole abnormality
in circulating androgens observed in w10% of women
with PCOS (43, 44). Therefore, it is difficult to think that
this hyperactivity of the adrenal gland may play a
protective role regarding the risk of diabetes in women
with PCOS, as suggested by some evidences (36, 45).
Certainly, the role of adrenal androgens in the metabolicwww.eje-online.org
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that there are also studies suggesting a positive association
between high DHEAS levels and metabolic disturbances
such as hypertension (46, 47).
We feel that these hypotheses on the possible
protective metabolic role of DHEAS in women with
PCOS may be influenced by what is observed in post-
menopausal women and even more in men, in which
age-related reduction of DHEAS is associated with an
increased cardiometabolic risk (48, 49).
In women with PCOS, the increase in DHEAS is to be
observed mainly as a result of hyperinsulinism (compen-
sating a state of insulin resistance), which is usually
associated with the syndrome (50); it is known that
administration of exogenous insulin appears to induce
adrenocortical androgen production in womenwith PCOS
through stimulation of 17-hydroxylase activity (50);
moreover, a relationship between circulating insulin levels
and hyperandrogenism in women with PCOS is further
suggested by the ability of insulin-sensitizing drugs to
reduce ovarian and adrenal androgen production (51, 52).
In our study, an association between DHEAS and
indices of insulin sensitivity (HOMA2-IR, ISI Matsuda)
was not found, but, surprisingly, DHEAS correlated
positively with DIO, which expresses insulin secretion
secondary to a certain degree of insulin sensitivity (i.e.
compensatory hyperinsulinism) (23). This could be
explained by insulin action on adrenal cortex: in women
of childbearing age, the compensatory hyperinsulinism
may play a synergistic role with ACTH with regard to
the synthesis of DHEAS (50).
Among the limitations of this retrospective study,
mention should be made of the sample size, which did
not allow us to assess the predictive markers studied after
subdividing women with PCOS into the different pheno-
types derived from application of the Rotterdam criteria
(the subdivision into four phenotypes did significantly
reduce the statistical power of the study). Another
limitation of the study is the use of antibody-based
assays for steroid levels; in further studies, this limitation
could be overcome by the use of liquid chromatography–
mass spectrometry, which in our hospital is rarely used
at the moment due to the high costs of materials, the
special skills required, and poor practicality for a large
series of assays.
In conclusion, the VAI and DHEAS may be considered
useful tools for prescreening in all women with PCOS with
no obvious classical risk factors for diabetes (normal
weight, absence of family history, and normal fasting
glucose). In the future, further studies could also evaluatewww.eje-online.orgthe usefulness of these tools even in those women who
meet only one of the three diagnostic criteria of PCOS.Declaration of interest
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